Clinical Data Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off BioSpaceSanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a "measured risk."Clinical DataImmunology & InflammationRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) BioSpace Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.” Clinical DataImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Sanofi immune drug hopeful posts mixed results in mid-stage testsNext: In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
